Biogen Idec (BIIB) Could Be One To Watch On ImClone Bid
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Join SI Premium – FREE
Watch Biogen Idec Inc. (Nasdaq: BIIB) on news that Bristol-Myers Squibb Co. (NYSE: BMY) offered to acquire ImClone (Nasdaq: IMCL) at a hefty premium of $60 per share.
Carl Icahn is a shareholder of BIIB and IMCL.
Carl Icahn is a shareholder of BIIB and IMCL.
Create E-mail Alert Related Categories
Insiders' Blog, Rumors, Trader TalkRelated Entities
Carl IcahnSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
